Baxter Healthcare is set to acquire Cheetah Medical, a firm an analyst identified earlier this year as one of 16 disruptive private companies in medtech.

The transaction consists of an upfront cash consideration of $190 million, with potential for an additional $40 million based on clinical and commercial milestones. It is set to close in 4Q19.

Boston and Tel Aviv, Israel-based Cheetah Medical is a major provider of non-invasive hemodynamic monitoring technologies.

The addition of Cheetah Medical is expected to enhance Deerfield, IL-based Baxter’s presence in the specialized patient monitoring space with key technology used to guide fluid management—a critical aspect of patient care—as too little or too much fluid can increase mortality and risk of complications.

Cheetah Medical said its Starling SV platform uses its Bioreactance technology to calculate stroke volume and additional hemodynamic parameters, providing a real-time assessment of heart function in critical care or surgical patients to ensure adequate blood perfusion and optimal fluid management.

The platform is completely noninvasive, holds broad applicability and is easy to use, and can provide dynamic assessments of fluid responsiveness to aid in physician treatment decision making.

In a release, David Ferguson, general manager, Medication Delivery, for Baxter, said, “the robust capabilities and innovative monitoring technologies we will gain with the acquisition of Cheetah Medical will be additional strategic growth drivers as we work to eliminate preventable harm and enable personalized therapy for hospitalized patients around the world.”

Earlier this year, Baxter made a list MD+DI compiled of companies from their earnings reports that indicated whether the firms were still hot for M&A in 2019 – or not.

In its 4Q18 earnings call, Baxter CEO José Almeida said, “we continue very aggressively looking for opportunities, and I want you guys to think about not on the size base, but more so on adjacencies and things that’ll make sense for our company, for Baxter, according to a Seeking Alpha Transcript.

And in January, Cheetah made Canaccord Genuity Analyst, Jason Mills’ list of 16 potentially promising medtech companies in the private sector.

In the January research note, Mills wrote, "Cheetah is planning to leverage its current sales infrastructure to drive growth in 2019, with management noting it could potentially look to add additional geographies to its current 20 territories over the next few years, with the potential addition of territory specialists further driving adoption down the road.”